Publications

Recent publications of the EUTOS 2024 project:

Curik N, Laznicka A, Krizkova J, Suchankova P, Vavrova A, Polivkova V, Pokorna E, Semerak P, Burda P, Kuzilkova D, Kalina T, Hochhaus A, Machova Polakova K. Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia. Leukemia. 2025 Oct;39(10):2555-2558. doi: 10.1038/s41375-025-02732-1. Epub 2025 Aug 26. PMID: 40858806

Curik N, Laznicka A, Polivkova V, Krizkova J, Pokorna E, Semerak P, Suchankova P, Burda P, Hochhaus A, Machova Polakova K. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations. Leukemia. 2024 Jun;38(6):1415-1418. doi: 10.1038/s41375-024-02248-0. Epub 2024 Apr 13. PMID: 38615117

Oliinyk D, Will A, Schneidmadel FR, Böhme M, Rinke J, Hochhaus A, Ernst T, Hahn N, Geis C, Lubeck M, Raether O, Humphrey SJ, Meier F. µPhos: a scalable and sensitive platform for high-dimensional phosphoproteomics. Mol Syst Biol. 2024 Aug;20(8):972-995. doi: 10.1038/s44320-024-00050-9. Epub 2024 Jun 21. PMID: 38907068

Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P, Kim D, Potdar S, Wolf M, Lotfi K, Aittokallio T, Wennerberg K, Porkka K, Mustjoki S. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia. Cell Rep Med. 2024 May 21;5(5):101521. doi: 10.1016/j.xcrm.2024.101521. Epub 2024 Apr 22. PMID: 38653245

Krizkova J, Polivkova V, Laznicka A, Curik N, Benesova A, Suchankova P, Smazik T, Vysinova V, Mikulenkova D, Klamova H, Markova MS, Srbova D, Zuna J, Zaliova M, Trka J, Salek C, Polakova KM. Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia. Leukemia. 2025 Jul;39(7):1670-1677. doi: 10.1038/s41375-025-02609-3. Epub 2025 Apr 28. PMID: 40295826

Ruess, D.A., Hantschel, O. Zielgerichtete Therapie mit allosterischen Inhibitoren. Onkologie 31, 470–476 (2025). doi: 10.1007/s00761-024-01663-3.

Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, Rees D, Byrne J, Gallipoli P, Francis S, Copland M, Horne G, Raghavan M, Arnold C, Collins A, Cranfield T, Cunningham N, Danga A, Forsyth P, Frewin R, Garland P, Hannah G, Avenoso D, Hassan S, Huntly BJP, Husain J, Makkuni S, Rothwell K, Khorashad J, Apperley JF, Milojkovic D. Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leukemia. 2024 Nov;38(11):2443-2455. doi: 10.1038/s41375-024-02411-7. Epub 2024 Sep 17. PMID: 39300220

Ernst P, Rinke J, Franke GN, Dicker F, Haferlach T, Ernst T, Hochhaus A. Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation. Leukemia. 2024 Sep;38(9):2037-2040. doi: 10.1038/s41375-024-02327-2. Epub 2024 Jul 4. PMID: 38965368

Recent publications of the EUTOS 2022 project:

Salmon M, White HE, Zizkova H, Gottschalk A, Motlova E, Cerveira N, Colomer D, Coriu D, Franke GN, Gottardi E, Izzo B, Jurcek T, Lion T, Schäfer V, Venturi C, Vigneri P, Zawada M, Zuna J, Hovorkova L, Koblihova J, Klamova H, Markova MS, Srbova D, Benesova A, Polivkova V, Zackova D, Mayer J, Roeder I, Glauche I, Ernst T, Hochhaus A, Polakova KM, Cross NCP. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia. 2022 Jul;36(7):1879-1886. doi: 10.1038/s41375-022-01612-2. Epub 2022 Jun 8. PMID: 35676453

Schönfeld L, Rinke J, Hinze A, Nagel SN, Schäfer V, Schenk T, Fabisch C, Brümmendorf TH, Burchert A, le Coutre P, Krause SW, Saussele S, Safizadeh F, Pfirrmann M, Hochhaus A, Ernst T. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia. 2022 Sep;36(9):2242-2249. doi: 10.1038/s41375-022-01648-4. Epub 2022 Jul 28. PMID: 35902731

Soverini S, De Santis S, Martelli M, Monaldi C, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Bruno S, Venturi C, Machova Polakova K, Ernst T, Maar D, Corner A, Cavo M. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia. Leukemia. 2022 Sep;36(9):2250-2260. doi: 10.1038/s41375-022-01660-8. Epub 2022 Jul 30. PMID: 35908105

White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, Barbany G, Cayuela JM, Cerveira N, Cochaux P, Colomer D, Coriu D, Diamond J, Dietz C, Dulucq S, Engvall M, Franke GN, Gineikiene-Valentine E, Gniot M, Gómez-Casares MT, Gottardi E, Hayden C, Hayette S, Hedblom A, Ilea A, Izzo B, Jiménez-Velasco A, Jurcek T, Kairisto V, Langabeer SE, Lion T, Meggyesi N, Mešanović S, Mihok L, Mitterbauer-Hohendanner G, Moeckel S, Naumann N, Nibourel O, Oppliger Leibundgut E, Panayiotidis P, Podgornik H, Pott C, Rapado I, Rose SJ, Schäfer V, Touloumenidou T, Veigaard C, Venniker-Punt B, Venturi C, Vigneri P, Vorkinn I, Wilkinson E, Zadro R, Zawada M, Zizkova H, Müller MC, Saussele S, Ernst T, Machova Polakova K, Hochhaus A, Cross NCP. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 2022 Jul;36(7):1834-1842. doi: 10.1038/s41375-022-01607-z. Epub 2022 May 25. PMID: 35614319

Hehlmann R, Lauseker M, Voskanyan A, Fabarius A, Haferlach C, Hochhaus A, Saußele S. Impact of emerging ACA on survival in chronic myeloid leukemia (CML). Leukemia. 2022 Oct;36(10):2544-2547. doi: 10.1038/s41375-022-01681-3. Epub 2022 Aug 23. PMID: 35999258

Lauseker M, Hehlmann R, Hochhaus A, Saußele S. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023 Nov;37(11):2231-2236. doi: 10.1038/s41375-023-02028-2. Epub 2023 Sep 19. PMID: 37726340

Chen Y, Möbius S, Riege K, Hoffmann S, Hochhaus A, Ernst T, Rudolph KL. Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution. Leukemia. 2023 Jul;37(7):1561-1566. doi: 10.1038/s41375-023-01929-6. Epub 2023 May 26. PMID: 37237078

Benesova A, De Santis S, Polivkova V, Pecherkova P, Krizkova J, Suchankova P, Monaldi C, Klamova H, Srbova D, Zizkova H, Hochhaus A, Soverini S, Machova Polakova K. Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia. Am J Hematol. 2024 Apr;99(4):759-762. doi: 10.1002/ajh.27232. Epub 2024 Feb 5. PMID: 38314531

Huuhtanen J, Adnan-Awad S, Theodoropoulos J, Forstén S, Warfvinge R, Dufva O, Bouhlal J, Dhapola P, Duàn H, Laajala E, Kasanen T, Klievink J, Ilander M, Jaatinen T, Olsson-Strömberg U, Hjorth-Hansen H, Burchert A, Karlsson G, Kreutzman A, Lähdesmäki H, Mustjoki S. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia. 2024 Jan;38(1):109-125. doi: 10.1038/s41375-023-02074-w. Epub 2023 Nov 2. PMID: 37919606

Leyte-Vidal A, Garrido Ruiz D, DeFilippis R, Leske IB, Rea D, Phan S, Miller KB, Hu F, Mase A, Shan Y, Hantschel O, Jacobson MP, Shah NP. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood. 2024 Aug 8;144(6):639-645. doi: 10.1182/blood.2023022538. PMID: 38643492

Recent publications of the EUTOS 2018 project:

Katerina Machova Polakova, Hana Zizkova, Jan Zuna, Eliska Motlova, Lenka Hovorkova, Andrea Gottschalk, Ingmar Glauche, Jitka Koblihova, Pavla Pecherkova, Hana Klamova, Marketa Stastna Markova, Dana Srbova, Adela Benesova, Vaclava Polivkova, Tomas Jurcek, Daniela Zackova, Jiri Mayer, Thomas Ernst, Francois X. Mahon, Susanne Saussele, Ingo Roeder, Nicholas C. P. Cross & Andreas Hochhaus. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia. 2020. https://doi.org/10.1038/s41375-020-0882-1

Möbius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). J Cancer Res Clin Oncol. 2019 Jun;145(6):1645-1650. doi: 10.1007/s00432-019-02910-6. Epub 2019 Apr 2. PMID: 30941573

Schäfer V, White HE, Gerrard G, Möbius S, Saussele S, Franke GN, Mahon FX, Talmaci R, Colomer D, Soverini S, Machova Polakova K, Cross NCP, Hochhaus A, Ernst T. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. J Cancer Res Clin Oncol. 2021 Oct;147(10):3081-3089. doi: 10.1007/s00432-021-03569-8. Epub 2021 Mar 7. PMID: 33677711

Loncarevic IF, Toepfer S, Hubold S, Klingner S, Kanitz L, Ellinger T, Steinmetzer K, Ernst T, Hochhaus A, Ermantraut E. Ultra-precise quantification of mRNA targets across a broad dynamic range with nanoreactor beads. PLoS One. 2021 Mar 18;16(3):e0242529. doi: 10.1371/journal.pone.0242529. PMID: 33735175

Rinke J, Hochhaus A, Ernst T. CML - Not only BCR-ABL1 matters. Best Pract Res Clin Haematol. 2020 Sep;33(3):101194. doi: 10.1016/j.beha.2020.101194. Epub 2020 Jun 7. PMID: 33038988

Inselmann S, Wang Y, Saussele S, Fritz L, Schütz C, Huber M, Liebler S, Ernst T, Cai D, Botschek S, Brendel C, Calogero RA, Pavlinic D, Benes V, Liu ET, Neubauer A, Hochhaus A, Burchert A. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. Cancer Res. 2018 Nov 1;78(21):6223-6234. doi: 10.1158/0008-5472.CAN-18-1477. Epub 2018 Aug 30. PMID: 30166420

Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2018 Apr;32(4):1054. doi: 10.1038/leu.2017.348. Epub 2018 Jan 30. Erratum for: Leukemia. 2017 Apr;31(4):829-836. doi: 10.1038/leu.2017.9. PMID: 29381150

Kreutzman A, Yadav B, Brummendorf TH, Gjertsen BT, Hee Lee M, Janssen J, Kasanen T, Koskenvesa P, Lotfi K, Markevärn B, Olsson-Strömberg U, Stentoft J, Stenke L, Söderlund S, Udby L, Richter J, Hjorth-Hansen H, Mustjoki S. Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncoimmunology. 2019 Jul 13;8(9):e1638210. doi: 10.1080/2162402X.2019.1638210. PMID: 31428530

Michel, C., Burchert, A., Hochhaus, A., Saussele, S., Neubauer, A., Lauseker, M., et al.. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2019, 104(5), 955–962. http://doi.org/10.3324/haematol.2018.206797

Recent publications of the EUTOS 2016 project:

Cross NCP, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia. 2016;30:1844-52. doi: 10.1038/leu.2016.90 PMID: 27109508

Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen J, Ossenkoppele G, Porkka K, Wolf D.: Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor (TKI) therapy in early Chronic Phase Chronic Myelogenous Leukemia (CML-CP). J Clin Oncol. 2017. 35(2):175-184. PMID:28056193

Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2018 Apr;32(4):1054. doi: 10.1038/leu.2017.348. Epub 2018 Jan 30. PMID: 29381150

Sopper S, Mustjoki S, Gjertsen BT, et al. NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. Leukemia. 2017 Oct;31(10):2264-2267. DOI: 10.1038/leu.2017.235.

Brück O, Blom S, Dufva O, et al. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia. 2018;32(7):1643‐1656. DOI:10.1038/s41375-018-0175-0

Inselmann et al., Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia. (2018). Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia. Cancer Res. 2018 (78) (21) 6223-6234; http://doi.org/10.1158/0008-5472.CAN-18-1477

Michel C, Burchert A, Hochhaus A, et al. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2019;104(5):955‐962. DOI:10.3324/haematol.2018.206797

Möbius S, Schenk T, Himsel D, et al. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). J Cancer Res Clin Oncol. 2019;145(6):1645‐1650. DOI:10.1007/s00432-019-02910-6